TrialBlood advances2022

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Lionel Adès et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.